We are live on ! Find out more
LXEO icon

Lexeo Therapeutics
LXEO

139 hedge funds and large institutions have $459M invested in Lexeo Therapeutics in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

548% more call options, than puts

Call options by funds: $389K | Put options by funds: $60K

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

4.7% more ownership

Funds ownership: 104.76% → 109.46% (+4.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 146 → 139 (-7)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

40% less capital invested

Capital invested by funds: $759M → $459M (-$300M)

Holders
139
Holders Change
-7
Holders Change %
-4.79%
% of All Funds
1.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
21
Increased
58
Reduced
38
Closed
27
Calls
$389K
Puts
$60K
Net Calls
+$329K
Net Calls Change
+$336K

Top Buyers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
+$13.1M
2
O
OrbiMed
New York
+$10.5M
3
PBA
Paradigm Biocapital Advisors
New York
+$10.1M
4
Goldman Sachs
Goldman Sachs
New York
+$8.28M
5
SSC
Spruce Street Capital
New York
+$5.34M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$10.1M
2
SL
Siren LLC
Connecticut
-$7.16M
3
SCM
Silverarc Capital Management
Massachusetts
-$6.13M
4
OCA
Octagon Capital Advisors
New York
-$4.43M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$4.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
SS
126
SBI Securities
Japan
$1.19K -$71 -10 -5%
FFO
127
Fortitude Family Office
Arizona
$1.18K +$574 +81 +65%
IA
128
IFP Advisors
Florida
$1.17K – – –
S
129
SignatureFD
Georgia
$1.15K -$638 -90 -31%
KFI
130
Key Financial Inc
Pennsylvania
$1.15K +$1.42K +200 New
TM
131
Torren Management
California
$1.02K -$1.01K -143 -45%
SPIA
132
Steward Partners Investment Advisory
New York
$574 – – –
BFS
133
Bare Financial Services
Pennsylvania
$459 +$567 +80 New
CIAM
134
Caitong International Asset Management
Hong Kong
$344 -$25.9K -3,654 -98%
UBS AM
135
UBS AM
Illinois
$321 +$397 +56 New
BWA
136
Basecamp Wealth Advisors
Washington
$166 -$595 -84 -74%
SS
137
Sunbelt Securities
Texas
$92 – – –
MCM
138
MAI Capital Management
Ohio
$64 +$78 +11 New
SAM
139
Smartleaf Asset Management
Massachusetts
$21 – – –
SL
140
Siren LLC
Connecticut
– -$7.16M -720,622 Closed
SCM
141
Silverarc Capital Management
Massachusetts
– -$6.13M -617,608 Closed
Verition Fund Management
142
Verition Fund Management
Connecticut
– -$4.25M -428,458 Closed
Ameriprise
143
Ameriprise
Minnesota
– -$2.42M -243,294 Closed
Renaissance Technologies
144
Renaissance Technologies
New York
– -$2.16M -217,772 Closed
Jane Street
145
Jane Street
New York
– -$993K -140,096 Closed
PA
146
Perceptive Advisors
New York
– -$1.39M -139,835 Closed
Two Sigma Advisers
147
Two Sigma Advisers
New York
– -$807K -81,300 Closed
AI
148
Atom Investors
Texas
– -$680K -68,491 Closed
Acadian Asset Management
149
Acadian Asset Management
Massachusetts
– -$505K -50,909 Closed
American Century Companies
150
American Century Companies
Missouri
– -$457K -45,988 Closed
3 4 5
6
7

LXEO Hedge Fund Activity: Q1 2026 in Review

139 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q1 2026, worth a combined $459M — down 40% from $759M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of LXEO and 21 opened new positions — a net loss of 6 holders — while 38 trimmed existing stakes and 58 added.

The largest buyer was Affinity Asset Advisors, adding an estimated $13.1M. The largest seller was Avoro Capital Advisors, cutting an estimated $10.1M.

  • 139 institutional investors held Lexeo Therapeutics (LXEO) as of Q1 2026, down from 146 in Q4 2025.
  • Funds reported $459M of Lexeo Therapeutics stock for Q1 2026, down 40% quarter-over-quarter.
  • 21 funds opened new Lexeo Therapeutics positions in Q1 2026 and 27 closed out, a net change of -6 holders.
  • The largest Lexeo Therapeutics buyer in Q1 2026 was Affinity Asset Advisors, an estimated $13.1M added.
  • The largest Lexeo Therapeutics seller in Q1 2026 was Avoro Capital Advisors, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2026.